Outlook Therapeutics, Inc.
- OTLK
- NASDAQ
- Biotechnology
- Ophthalmology Biotech
- Monoclonal Antibody Therapeutics
$0.49
Today +0.98%Quote Oct 19, 2026, 08:00 PM UTC
−24.46%over the last month
Max drawdown −32.5%From 1-month high −29.2%3 months −65.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
17
Founded
2010
Market value
$120.0M
Quote Oct 19
Floor
$0.46
6.9% below price
Resistance
$0.51
3.2% above price
Price vs analyst targets
14 analysts
Lowest target
$1.60Highest target
$4.00
$1.60Highest target
$4.00
- Price $0.49
- Average target $2.80
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 468% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about OTLKPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free